NeoPhore Appoints Michael Shih as CEO to Propel Cancer Research
Portfolio - People | Dec 16, 2024 | EIN
NeoPhore Limited, a UK-based biotech company specializing in small molecule therapies for cancer treatment, has appointed Michael Shih as its new Chief Executive Officer. Shih, with nearly two decades of expertise in corporate development and a rich history in business development roles at Kite Pharma, Biogen, and Sanofi, is expected to focus on driving NeoPhore's growth strategy. The company's recent Series B financing round, supported by Bristol Myers Squibb, indicates a robust financial position. NeoPhore's innovative approach targets the MMR pathway to enhance cancer immunotherapy, marking a significant advancement toward becoming a clinical company.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- United Kingdom – NeoPhore Limited is based in the UK, making this the primary geography for the company’s operations.
Industry
- Biotechnology – NeoPhore operates in the biotechnology sector, focusing on the development of small molecule therapies to treat cancer.
- Pharmaceuticals – The company's pipeline targets cancer treatment, placing it within the pharmaceutical industry focusing on drug discovery and development.
Financials
- Series B financing – NeoPhore raised a significant amount in its Series B financing round, with support from Bristol Myers Squibb.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| NeoPhore Limited | Target Company | Company | A UK-based biotech firm focused on developing cancer treatments through the stimulation of the immune system targeting the MMR pathway. |
| Michael Shih | Chief Executive Officer | Person | Newly appointed CEO of NeoPhore, with extensive experience in corporate development in the pharma and biotech sectors. |
| Kite Pharma | Former Employer | Company | Previous employer of Michael Shih where he served as Vice President of Corporate Development. |
| Biogen | Former Employer | Company | Former workplace of Michael Shih, where he was Senior Vice President, Head of Business Development. |
| Sanofi | Former Employer | Company | Company where Michael Shih previously worked as Vice President and Head of Global Transactions. |
| Bristol Myers Squibb | Investor | Company | Supported NeoPhore's recent Series B financing round. |
| Robert James | Chairman of the Board | Person | Chairman of the Board of NeoPhore. |